Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy S Tracy

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Nanotechnology|March 26, 2015
Nanoscale electron transport measurements of immobilized cytochrome P450 proteinsChristopher D Bostick, Darcy R Flora, Peter M Gannett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 7, 2022
<b>Pharmacokinetic Modeling of Warfarin І - Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals </b>Shen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 15, 2022
A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various <i>CYP2C9</i> Genotypes under Different CotreatmentsShen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 7, 2022
<b>Pharmacokinetic Modeling of Warfarin ІI - Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin</b>Shen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 25, 2006
Enzyme source effects on CYP2C9 kinetics and inhibitionVikas Kumar, Dan A Rock, Chad J Warren, et al.
Archives of Biochemistry and Biophysics|February 1, 2003
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observationsJ Matthew Hutzler, Larry C Wienkers, Jan L Wahlstrom, et al.
British Journal of Clinical Pharmacology|December 4, 2003
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patientsEric B Belldina, Mei Y Huang, Jerry A Schneider, et al.
Biochemical Pharmacology|May 8, 2004
Differential activation of CYP2C9 variants by dapsoneMatthew A Hummel, Leslie J Dickmann, Allan E Rettie, et al.
Pharmacogenetics and Genomics|May 2, 2012
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3Murali Subramanian, Vishal Agrawal, Duanpen Sandee, et al.
American Journal of Pharmaceutical Education|August 14, 2008
Your role and responsibilities in the manuscript peer review processGayle A Brazeau, Joseph T Dipiro, Jack E Fincham, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Nanotechnology|March 26, 2015
Nanoscale electron transport measurements of immobilized cytochrome P450 proteinsChristopher D Bostick, Darcy R Flora, Peter M Gannett, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 7, 2022
<b>Pharmacokinetic Modeling of Warfarin І - Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals </b>Shen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 15, 2022
A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various <i>CYP2C9</i> Genotypes under Different CotreatmentsShen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 7, 2022
<b>Pharmacokinetic Modeling of Warfarin ІI - Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin</b>Shen Cheng, Darcy R Flora, Allan E Rettie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 25, 2006
Enzyme source effects on CYP2C9 kinetics and inhibitionVikas Kumar, Dan A Rock, Chad J Warren, et al.
Archives of Biochemistry and Biophysics|February 1, 2003
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observationsJ Matthew Hutzler, Larry C Wienkers, Jan L Wahlstrom, et al.
British Journal of Clinical Pharmacology|December 4, 2003
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patientsEric B Belldina, Mei Y Huang, Jerry A Schneider, et al.
Biochemical Pharmacology|May 8, 2004
Differential activation of CYP2C9 variants by dapsoneMatthew A Hummel, Leslie J Dickmann, Allan E Rettie, et al.
Pharmacogenetics and Genomics|May 2, 2012
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3Murali Subramanian, Vishal Agrawal, Duanpen Sandee, et al.
American Journal of Pharmaceutical Education|August 14, 2008
Your role and responsibilities in the manuscript peer review processGayle A Brazeau, Joseph T Dipiro, Jack E Fincham, et al.
Pageof 8